# A Study to Evaluate the Utilization, Effectiveness, and Quality of Life of Ozanimod in Participants With Ulcerative Colitis

> **NCT05382715** · — · TERMINATED · sponsor: **Bristol-Myers Squibb** · enrollment: 175 (actual)

## Conditions studied

- Colitis, Ulcerative

## Interventions

- **DRUG:** Ozanimod

## Key facts

- **NCT ID:** NCT05382715
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2022-05-30
- **Primary completion:** 2025-05-31
- **Final completion:** 2025-05-31
- **Target enrollment:** 175 (ACTUAL)
- **Why stopped:** Business objectives have changed
- **Last updated:** 2025-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05382715

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05382715, "A Study to Evaluate the Utilization, Effectiveness, and Quality of Life of Ozanimod in Participants With Ulcerative Colitis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05382715. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*